Novo Nordisk, Inc. recently commissioned Milliman to analyze the incremental impact of coverage of anti-obesity medications (AOMs) approved by the Food and Drug Administration in the Medicaid and commercial markets. In the past several years, the perception of obesity treatments have evolved from cosmetic drugs to vehicles to treat a chronic condition. There also have been advances in AOMs, specifically glucagon-like peptide-1 agonists. In this paper, we cover the AOM landscape, recent market events, and coverage. We discuss the following results and topics:

• Medicaid market impact
• Commercial market impact
• Other considerations
• Sensitivity testing

This report was commissioned by Novo Nordisk, Inc.